Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary

Recruiting now · Phase 2

Conditions studied: Neuroendocrine Carcinoma

In brief

there is a need for improving chemotherapy regimen for metastatic G3 NEC of GEP and Unknown origin and this goal may be achieved through more "personalized" chemotherapy regimen.the hypothesis is that mFOLFIRINOX regimen could be a good candidate for challenging the platinum-etoposide regimen in patients with metastatic G3 NEC of GEP or unknown origin. Furthermore, in order to get insights in the putative predictive biomarkers of efficacy of these two regimens, an effort toward a precise molecular characterization of these tumors is required in order to be able to define which subgroup of G3 NEC needs to be treated by which chemotherapy regimen. The FOLFIRINEC trial is set up in order to try to answer these questions

Key facts

Study ID

NCT04325425

Run by

Centre Hospitalier Universitaire Dijon

People needed

218

Starts

2020-09-01

Expected to finish

2029-09-01

Last updated by the study team

2025-09-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Grade 3 neuroendocrine carcinoma or high grade MiNEN with a grade 3 poorly differentiated neuroendocrine carcinoma component ≥30% of gastro-entero-pancreatic or unknown primary
• Poorly differentiated
• Small cell or large cell or non-small cell or non- typeable
• Metastatic disease
• First-line, no prior therapy for metastatic disease, no prior use of carboplatin, oxaliplatin, cisplatin, etoposide, irinotecan and 5-fluorouracile
• At least one measurable lesion as assessed by CT-scan or MRI according to RECIST 1.1 guidelines
• Available tumor block
• ANC ≥ 1.5x109/l, platelet ≥ 100x109/l and hemoglobin > 8 g/dl
• Total bilirubin ≤ 1.5N, AST ≤ 2.5N, ALT≤ 2.5N or AST/ALT ≤ 5N in case of liver metastases.
• Age ≥ 18 years
• ECOG Performance Status ≤ 1
• Signed and dated informed consent, and willing and able to comply with protocol requirements.
• Women of childbearing potential, as well as men (who have sexual relations with women of childbearing potential) must agree to use an effective method of contraception throughout this study and during the 15 months following administration of the last dose of the study medicinal product
• Patient who is a beneficiary of the Social security system

You may not qualify if…

• Grade 3 well differentiated neuroendocrine tumor according to WHO 2017 classification
• Severe renal impairment (creatinine clearance less than 30 mL/min, MDRD)
• Partial or complete Dihydropyrimidine Dehydrogenase (DPD) deficiency (uracilemia ≥ 16 ng/mL)
• Gilbert's syndrome
• Pre-existing permanent neuropathy (NCI CTC V4.0 grade ≥2)
• Previously treated by chemotherapy or targeted therapy
• Brain metastases unless they are asymptomatic or under stable corticosteroid doses for 2 weeks otherwise. Radiation therapy prior to inclusion is required if symptomatic.
• Combination with sorivudine and others analogues as brivudine (irreversibly inhibits the enzyme dihydropyrimidine dehydrogenase)
• Treatment with St John's Wort (Hypericum perforatum)
• Pregnant women or breastfeeding mother
• Known or historical active infection with HIV, or known active infection untreated with hepatitis B or hepatitis C
• History of prior malignancy, except for cured non-melanoma skin cancer, cured in situ cervical carcinoma, or other treated malignancies with no evidence of disease for at least three years.
• Active or suspected acute or chronic uncontrolled disease that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study
• vaccinations (live vaccine) within 30 days prior to start of study drugs
• Patient under guardianship and/or deprived of his/her freedom
• QT/QTc interval > 450 msec for male and > 470 msec for female at EKC.
• K+ < LLN, Mg²+ < LLN, Ca²+ < LLN
• History or know hypersensitivity to any of the study chemotherapy agents, or their excipients

Where it is running

• Chu de Caen — Caen, France (enrolling)
• Chu Dijon Bourgogne — Dijon, France (enrolling)
• Institut de Cancérologie de Bourgogne — Dijon, France (enrolling)
• Chu de Limoges - Dupuytren — Limoges, France (enrolling)
• Centre Hospitalier de Saint Malo — St-Malo, France (enrolling)
• CH de Troyes — Troyes, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.